In a Grade A aseptic filling line equipped with a restricted access barrier system (RABS), sterile cefazolin sodium is transferred from double-layered polyethylene bags through a split butterfly valve into a temperature- and humidity-controlled hopper. The crystalline powder is filled into pre-sterilized Type I glass vials using a vacuum or screw auger filler under unidirectional airflow of 0.45 m/s ± 20%. Each vial is sealed with a halogenated butyl rubber stopper and an aluminium flip-off cap. The product is a sterile dry powder for reconstitution before intravenous or intramuscular administration. Because cefazolin sodium contains approximately 2.1 mmol of sodium per 1 g of active ingredient, fill-weight targets are verified by 100% gravimetric checkweighing. Vial washing is performed with water for injection at 80 °C, followed by depyrogenation at 250 °C for a validated exposure time. Terminal steam sterilization is avoided because the β-lactam ring undergoes hydrolysis at elevated temperature and at pH values outside the stable range. In-process controls include loss on drying, sterility testing by USP <71>, bacterial endotoxins testing by USP <85>, and particle size distribution. The sterility assurance level after aseptic filling is validated by media fills using tryptic soy broth. Batch release requires all units to remain within the validated fill-weight tolerance and environmental monitoring to show no excursion beyond Grade A limits. The terminal product is a single-dose vial of cefazolin sodium injection with immediate-release behaviour after reconstitution. The sodium content must be declared when used in patients on sodium-restricted regimens. This filling route is the largest downstream consumption pattern for the sterile API.

What Limits Shelf Life After Reconstitution in Infusion Admixtures?

Reconstitution of cefazolin sodium in a central intravenous admixture unit begins with adding 10 mL of sterile water for injection to a 1 g vial to yield a primary solution of 100 mg/mL. The primary solution is then transferred through a closed-system transfer device into 0.9% sodium chloride injection or 5% dextrose injection to produce final concentrations from 5 mg/mL to 20 mg/mL. The beyond-use date is constrained by β-lactam hydrolysis in aqueous solution. Degradation accelerates above pH 6.0 and below pH 4.0. The pH of maximum stability is approximately 4.5 to 5.5. Aminoglycoside antibiotics are not added to the same container because β-lactam ring cleavage can physically inactivate the aminoglycoside and produce visible precipitates. The reconstituted solution is also not combined with strongly alkaline drugs such as sodium bicarbonate unless compatibility is demonstrated by validated Y-site testing. Visible precipitation is a rejection criterion. The admixture container is labelled with the exact dose, osmolality, and expiration time. In hospital cleanrooms operating under USP <797>, low-risk compounded sterile preparations are assigned beyond-use dates of 48 hours at controlled room temperature or 14 days under refrigeration, but drug-specific labeling may require shorter dating. Aqueous solutions should not be frozen because ice formation can disrupt the amorphous solute matrix and cause unpredictable particle aggregation. Infusion via elastomeric pumps requires compatibility data for the elastomer reservoir and the flow restrictor. The terminal product is a ready-to-administer intravenous infusion that delivers the active drug over 30 to 60 minutes. If administered via intermittent intravenous infusion, the solution is attached to a vented infusion set with a 0.2 μm in-line filter. This filtration step protects against particulate contamination but does not remove endotoxins. The sterile API must therefore meet the bacterial endotoxin limit before the admixture is prepared.

For intramuscular administration, sterile cefazolin sodium is reconstituted immediately before use to avoid viscosity build-up and needle clogging caused by partial rehydration of the crystalline cake. The usual primary reconstitution is 1 g of cefazolin sodium with 2.5 mL of sterile water for injection, yielding a final concentration of approximately 330 mg/mL. In patients who require deep intramuscular delivery, the diluent may be 0.5% lidocaine hydrochloride injection instead of water. This substitution is intended to reduce injection pain but requires confirmation of local anesthetic compatibility. The resulting solution is drawn into a 21-gauge or larger needle to minimise shearing of particles during administration. The injection volume is limited to the dorsogluteal or vastus lateralis site. If a batch is reconstituted in a multi-dose setting, the vial must carry a beyond-use label under USP <797> and must be discarded if visible crystals or colour changes appear. The terminal product is an immediate-release intramuscular injection with peak plasma concentration typically reached within 30 to 60 minutes. Sterile API purity is critical because the intramuscular route bypasses gastrointestinal barriers and delivers the drug directly into highly vascularised tissue. pH of the reconstituted solution is monitored between 4.0 and 6.0. Solutions outside this range may cause tissue irritation or accelerated β-lactam cleavage. Hospitals that prepare intramuscular doses in advance should use validated closed-system devices and maintain sterile fill conditions in an ISO Class 5 environment.

When Cefazolin Sodium Is Compounded for Intracameral Ophthalmic Use

When cefazolin sodium is compounded for intracameral injection, the sterile API is not used as a dry powder at the point of surgery. A primary solution is first prepared to a known concentration using a closed-system reconstitution device inside a laminar-airflow compounding aseptic isolator. The solution is then diluted in balanced salt solution or other preservative-free ophthalmic irrigating solution. Published data for this specific configuration is limited, and no FDA-approved cefazolin sodium ophthalmic injection exists. The compounded preparation is therefore made under the direction of an ophthalmologist and assigned a short beyond-use date. Because the eye is an immunologically privileged site, the risk of endophthalmitis from contamination is high. Final filtration through a 0.2 μm sterilising-grade membrane is required before the syringe is capped and labelled. The terminal product is an intracameral injection or anterior chamber irrigation solution intended for surgical prophylaxis. The sodium content is an operational limitation because excess sodium in the anterior chamber may affect corneal endothelial cell function. The ionised cefazolin molecule is used for its narrow-spectrum Gram-positive coverage against common ocular surface contaminants, but the compounded form must be free of preservatives, buffers, and particulates. Compliance with USP <797> requires sterility and endotoxin testing of representative samples before the batch is released. Hospitals that prepare this product in advance must document the exact diluent, final concentration, storage temperature, and administration window. Unused syringes are discarded immediately after the procedure.

Peritoneal Dialysis Admixtures Are Prepared Under Aseptic Conditions in Hospital Pharmacy Cleanrooms

Peritoneal dialysis admixtures containing cefazolin sodium are prepared for the treatment of Gram-positive peritonitis in patients receiving continuous ambulatory peritoneal dialysis. The sterile API is reconstituted with sterile water or 0.9% sodium chloride injection and then injected into a dialysis solution bag containing 1.5%, 2.5%, or 4.25% dextrose. The final concentration is protocol-specific, and no universal ratio applies across all renal units. The injection port is swabbed with sterile alcohol and protected from touch contamination. The admixture bag is inverted gently to mix, avoiding vigorous shaking that may introduce bubbles. The terminal product is a ready-to-install peritoneal dialysis exchange. Because cefazolin sodium is stable over a narrow pH range, the addition to hypertonic dextrose solutions can accelerate β-lactam hydrolysis if the bag is stored too long. Beyond-use dating is therefore set to the shortest interval permitted by the drug monograph, USP <797>, and the dialysis unit's infection-control policy. The final admixture is inspected against a light source for colour, cloudiness, and particulate matter. Any bag with a visible precipitate is discarded. Published compatibility data for cefazolin sodium in different dialysate formulations is limited, so admixture validation is performed with the specific container material and dextrose concentration used in the unit. The route is only justified in patients with established peritoneal access. No oral absorption is involved.

Although cefazolin sodium is not suitable for conventional oral absorption because the ionised carboxylate group restricts passive diffusion across the gastric and jejunal epithelium, tablet, capsule, and granule development has been limited to investigational enteric-coated matrix systems. The free acid form of cefazolin is not produced as a stable oral candidate. The sodium salt is highly water-soluble and dissolves rapidly in stomach fluid, but the β-lactam ring is then hydrolysed in acidic gastric juice before systemic absorption can occur. No reference-listed oral cefazolin tablet exists in the United States. No USP monograph describes cefazolin sodium tablets or capsules. Consequently, downstream use of the sterile API in oral solid dosage forms is not a recognised commercial route. If an investigational formulation is prepared, the API is mixed with methacrylic acid-ethyl acrylate copolymer and compressed or extruded into granules. The granules are then coated with an enteric polymer designed to delay release until the distal small intestine or colon. Published human bioavailability data for cefazolin sodium enteric-coated granules is limited. Terminal product is an investigational drug product subject to institutional review board oversight and full safety review. The sterility requirement of the API is unnecessary for oral solid dosage development, but the crystalline form may still be tested for assay, related substances, and moisture content. Granule flowability is a critical processing attribute because irregular crystal habit can produce poor die filling and high weight variation. Adding 1 to 5% colloidal silicon dioxide or microcrystalline cellulose may be required to improve flow, but the selection must be based on compatibility studies. These formulations are not interchangeable with injectable drug products and are not intended for clinical use outside a controlled trial.

Veterinary Hospital Sterile Injection Compounding and Species-Specific Dosing Restrictions

Veterinary hospitals compound cefazolin sodium sterile API into injectable doses for companion animals, particularly dogs and cats, under veterinary prescription. The powder is reconstituted with sterile water for injection to 100 mg/mL or 330 mg/mL using the same aseptic technique as in human medicine. The terminal product is a syringed dose for subcutaneous, intramuscular, or intravenous administration. The US Food and Drug Administration prohibits extralabel use of cephalosporins in certain food-producing animals under 21 CFR 530.41. This prohibition exists because cephalosporin residues may compromise antibacterial therapy in humans and contribute to resistant zoonotic pathogens. In companion-animal practice, the API is used for perioperative prophylaxis and treatment of susceptible Gram-positive infections. Species-specific dosing is scaled to body weight and renal function. Renal impairment requires dose adjustment to avoid accumulation of the active drug. The sterile API lot used in veterinary compounding should meet the same endotoxin and sterility release criteria as human-grade material, but the regulatory pathway is different. If compounded outside an ISO Class 5 environment, the product is assigned an immediate-use beyond-use time. Repeated puncture of the multi-dose vial is a recognised contamination risk. The use of unpreserved reconstituted cefazolin sodium in a multi-dose container beyond the manufacturer's storage limit is prohibited. No oral dosage form is used in veterinary practice because of similar bioavailability limitations.